Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mercedes Balcells

Showing results (61-70 of 62) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 62 results.
Science Translational Medicine|November 24, 2017
Targeting STUB1-tissue factor axis normalizes hyperthrombotic uremic phenotype without increasing bleeding riskMoshe Shashar, Mostafa E Belghasem, Shinobu Matsuura, et al.
Circulation|August 11, 2017
Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis)David E Kandzari, Pieter C Smits, Michael P Love, et al.
Pageof 7

Showing results (61-70 of 62) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 62 results.
Science Translational Medicine|November 24, 2017
Targeting STUB1-tissue factor axis normalizes hyperthrombotic uremic phenotype without increasing bleeding riskMoshe Shashar, Mostafa E Belghasem, Shinobu Matsuura, et al.
Circulation|August 11, 2017
Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis)David E Kandzari, Pieter C Smits, Michael P Love, et al.
Pageof 7